Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of dapagliflozin on myocardial perfusion reserve in prediabetic patients with stable coronary artery disease
KCT0004802Phase 4Terminated
- Sponsor
- AstraZeneca
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in coronary arteriosclerosis, prediabetes, sponsored by AstraZeneca. Started May 2020; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
coronary arteriosclerosisprediabetes
Beyond the preview
Go deeper on KCT0004802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004802.